Innoviva, Inc. Common Stock
INVAStock
$22.21+9.67%52W
Market Cap$1.63B
P/E6.00x
Div yield—
Beta0.34
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)2.57%
Price vs S&P 500 (4W)-3.78%
VGM Score61.44
Market Capitalization$1.63B
P/E Ratio (Annual)6.00x
Earnings Surprise History
Q1 26-0.05est. 0.40
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.09
4.09
4.09
4.09
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
INVAInnoviva, Inc. Common Stock | B | C | C | $22.21 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Innoviva Inc generates revenue through a portfolio of pharmaceutical royalties and operating assets in critical care and infectious disease. Its holdings include branded respiratory therapies such as Trelegy, Anoro, and the Relvar/Breo/Ellipta franchise, which provide recurring revenue streams from established, marketed products.